

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

MM1.R

RRID:CVCL_8794

Type: Cell Line

Proper Citation

RRID:CVCL_8794

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8794

Proper Citation: RRID:CVCL_8794

Description: Cell line MM1.R is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:12691914](#), [PMID:17692805](#), [PMID:28196595](#), [PMID:32123307](#)

Comments: Characteristics: Resistant to dexamethasone., Characteristics: Produces IgA lambda (ATCC=CRL-2975)., Population: African American., Part of: MD Anderson Cell Lines Project.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MM1.R

Synonyms: MM1.r, MM.1R, MM1-R, MM-1R, MM1R, MM1.R(L), MM1.RL

Cross References: BTO:BTO_0003929, ABM:T8032, ATCC:CRL-2975, CCRID:3101HUMSCSP5050, Cell_Model_Passport:SIDM01264, Cosmic:1424219, Cosmic:2081429, GEO:GSM1374684, IZSLER:BS TCL 235, Wikidata:Q54906036

ID: CVCL_8794

Hierarchy: cvcl_5801

Record Creation Time: 20220427T220813+0000

Ratings and Alerts

No rating or validation information has been found for MM1.R.

No alerts have been found for MM1.R.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Murphy CS, et al. (2025) Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. Molecular oncology, 19(6), 1687.

Li S, et al. (2025) Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. Advanced healthcare materials, e02156.

Shearer T, et al. (2024) Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. Cancer research communications, 4(12), 3114.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. Research square.

Ticona-Pérez FV, et al. (2024) Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma. Cancer cell international, 24(1), 275.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Aubry A, et al. (2023) Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses. Cell reports, 42(8), 112925.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Ye L, et al. (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. *Cell metabolism*, 34(4), 595.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell chemical biology*, 28(4), 503.

Xiang P, et al. (2021) miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. *International journal of cancer*, 148(12), 3071.

Woan KV, et al. (2021) Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. *Cell stem cell*, 28(12), 2062.

Polusani SR, et al. (2021) Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma. *International journal of cancer*, 148(12), 3032.

Dickson P, et al. (2020) Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190. *Cell chemical biology*, 27(11), 1371.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. *Cell reports*, 31(13), 107840.

Dickson P, et al. (2020) Mechanistic Studies of the Multiple Myeloma and Melanoma Cell-Selective Toxicity of the Rpn13-Binding Peptoid KDT-11. *Cell chemical biology*, 27(11), 1383.

Amatuni A, et al. (2020) Concise Chemoenzymatic Total Synthesis and Identification of Cellular Targets of Cepafungin I. *Cell chemical biology*, 27(10), 1318.